Deltec Asset Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-100,000
Closed -$994K 294
2021
Q3
$994K Hold
100,000
0.15% 99
2021
Q2
$995K Hold
100,000
0.14% 105
2021
Q1
$996K Hold
100,000
0.15% 105
2020
Q4
$1.08M Hold
100,000
0.17% 98
2020
Q3
$1.04M Hold
100,000
0.19% 93
2020
Q2
$1M Buy
+100,000
New +$995K 0.21% 102

Other funds holding STLN

Deltec Asset Management's STLN Position: Q4 2021 in Review

Deltec Asset Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 100,000 shares — an estimated $994K sold.

Deltec Asset Management first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $1.08M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Deltec Asset Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Deltec Asset Management sold 100,000 Starling Oncology shares in Q4 2021, an estimated $994K.
  • Deltec Asset Management first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
  • Deltec Asset Management's Starling Oncology position peaked at $1.08M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Deltec Asset Management's 13F filing for Q4 2021, filed 25 Jan 2022.